BOURLA ALBERT 4

What Happened

• Albert Bourla, Chairman & CEO and a director of Pfizer (PFE), was granted 22 units that represent phantom shares of common stock on April 15, 2026. The units are recorded at $27.19 each for a total value of $598 (derivative award under Pfizer’s plans). This was an award/acquisition (not an open-market purchase or sale).

Key Details

• Transaction date: April 15, 2026; Form 4 filed April 17, 2026 (timely filing).
• Instrument: 22 units representing phantom shares; price/value per unit: $27.19; total value: $598.
• Shares owned after transaction: not specified in the Form 4 for actual common stock holdings.
• Footnotes: F1 — each unit = one phantom share of common stock. F2 — units were acquired under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan; they are cash-settled following separation from service and may be transferred by the reporting person into an alternative investment account at any time.
• Filing timeliness: no late filing flag; appears to be filed within the standard Form 4 timeframe.

Context

• These are phantom (cash‑settled) share units, not issuance of actual common stock; they are settled in cash after departure and therefore do not directly increase Bourla’s voting shares or immediately signal a stock purchase. The dollar amount is small (~$598), so this award is a routine compensation/deferred‑compensation item rather than a material insider market transaction.